https://www.selleckchem.com/pr....oducts/toyocamycin.h
Oncogenic KRAS is one of the most common drivers of human cancer. Despite intense research, no effective therapy to directly inhibit oncogenic KRAS has yet been approved and KRAS mutant tumors remain associated with a poor prognosis. This short review discusses the current knowledge of the redox regulation of RAS and examines the newest findings on cysteine 118 (C118) as a potential novel target for KRAS inhibition.The Kank (kidney or KN motif and ankyrin repeat domain-containing) family of proteins has been described as essential f
Like
Comment
Share
